Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!
Medicinal composition for curing cardiovascular diseases
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A composition and cardiovascular technology, applied in the field of medicine, can solve the problems of difficult absorption and low bioavailability of salidroside
Inactive Publication Date: 2012-10-10
杜超峰
View PDF0 Cites 7 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0004] Salidroside has a certain effect on treating cardiovascular diseases, but it has not been developed into a drug. The main reason is analyzed: salidroside is not easy to be absorbed, that is, the bioavailability is low; in animal experiments, factors such as large dosage, Therefore, the development of salidroside into new drugs requires further in-depth research
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0044] A pharmaceutical composition for treating cardiovascular diseases, the raw materials of which include salidroside, D-ribose, and ginsenoside Rb1. The above-mentioned raw materials are prepared into food or medicine, and the prepared dosage forms are tablets, capsules, granules, pills or oral liquids and the like.
[0045] The raw material can also contain salvianolic acid B, safflower yellow, ginsenoside Rg1, ligustrazine, paeoniflorin, musk ketone, eleutheroside, balsamic volatile oil, puerarin, ginkgolide, ginkgo flavonoids, jujube flavonoids, One or more of jujuberin, amygdalin, paeonol, American ginsenoside, aescin or sodium aescin, and icariin.
Embodiment 2
[0047] A pharmaceutical composition for treating cardiovascular diseases, the raw materials of which are salidroside 10g, D-ribose 1g and ginsenoside Rb1 3g. The above-mentioned raw materials are prepared into food or medicine, and the prepared dosage forms are tablets, capsules, granules, pills or oral liquids and the like.
Embodiment 3
[0049] A pharmaceutical composition for treating cardiovascular diseases, the raw materials of which are salidroside 1000g, D-ribose 200g and ginsenoside Rg1 55g. The above-mentioned raw materials are prepared into food or medicine, and the prepared dosage forms are tablets, capsules, granules, pills or oral liquids and the like.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention belongs to the technical field of medicaments or foods and discloses a medicinal composition. The medicinal composition comprises the following raw materials in part by weight: 10 to 1,000 parts of rhodioloside and 1 to 200 parts of D-ribose. The medicinal composition of the invention has a therapeutical effect on myocardial ischemia and anoxia, also can improve cardiovascular functions, controls the accumulation of blood platelets and the formation of thrombus, and has a certain effect of reducing blood lipid. The medicinal composition of the invention has the effects of tonifying qi, invigorating blood circulation, promoting coronary circulation and relieving pain, is used for chest obstruction which is caused by qi deficiency and blood stasis and is manifested as chest stuffiness, stabbing pain or dull pain, palpitation, short breath, fatigue, acratia, lack of qi and no desire to speak, light-headedness and the like, and is used for coronary heart disease and angina pectoris with above expressions.
Description
technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for treating cardiovascular diseases. Background technique [0002] In recent years, with the improvement of people's living standards in our country, the morbidity and mortality of coronary heart disease are showing an upward trend. There are currently about 50 million patients with coronary heart disease in my country, and about 300 patients die of cardiovascular and cerebrovascular diseases every hour. The incidence of coronary heart disease has been rising sharply in my country in recent years. According to a report by the World Health Organization, even if effective preventive measures are taken from now on, the rising trend of the incidence of cardiovascular diseases in my country will continue until about 2020. The ranking of cardiovascular and cerebrovascular drugs in the drug market has also risen to the second place, second on...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.